Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, dyslipidemia and bacterial infections used by patients around the world, the Group has also launched treatments for thrombotic disorders and is building new product franchises. Furthermore, Daiichi Sankyo research and development is focused on bringing forth novel therapies in oncology and cardiovascular-metabolic diseases, including biologics. The Daiichi Sankyo Group has created a “Hybrid Business Model,” to respond to market and customer diversity and optimize growth opportunities across the value chain.
For more information, please visit: www.daiichisankyo.com.
Content provided by sponsor:
- ESMO 2014 Poster: Phase 3 study of patritumab plus erlotinib in EGFR wild-type subjects with advanced non–small cell lung cancer
- ESMO 2014 Poster: Efficacy of patritumab (U3-1287), a fully human anti–human epidermal growth factor receptor 3 (HER3) monoclonal antibody, in head and neck cancer models
The European Society for Medical Oncology (ESMO) wishes to thank Daiichi Sankyo for donating this content.
ESMO only accepts content from third parties after careful evaluation of its educational and scientific relevance to the ESMO target audience. Eligible material should meet the essential criterion of non-promotional intent. Such material may be published in other resources, but the content donor has given permission to ESMO for use in OncologyPRO.